We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+6.58%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$160M
AUM Growth
+$37.8M
(+31%)
Cap. Flow
+$32.6M
Cap. Flow
% of AUM
20.39%
Top 10 Holdings %
Top 10 Hldgs %
54.86%
Holding
54
New
17
Increased
15
Reduced
14
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$9.48M |
| 2 |
Exicure
XCUR
|
+$5.81M |
| 3 |
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
|
+$4.75M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$4.74M |
| 5 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$4.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$6.04M |
| 2 |
Prothena Corp
PRTA
|
+$5.55M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$2.94M |
| 4 |
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
+$2.45M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$2.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.83% |
| 2 | Industrials | 2.39% |
| 3 | Energy | 1.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Prothena Corp
PRTA
$458M
| $21.7M | 13.57% |
422,000
-178,000
| -30% | -$5.55M |
|
|
ALBO
2
DELISTED
Albireo Pharma Inc
ALBO
| $10.4M | 6.49% |
295,080
+124,728
| +73% | +$4.06M |
|
|
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $9.34M | 5.84% |
137,000
+31,172
| +29% | +$2.03M |
|
|
4
Haemonetics
HAE
$3.58B
| $8.93M | 5.58% |
+134,000
| New | +$9.48M |
|
5
Cue Biopharma
CUE
$135M
| $7.34M | 4.59% |
21,012
+2,453
| +13% | +$951K |
|
6
Encompass Health
EHC
$11.2B
| $6.87M | 4.29% |
110,616
-15,084
| -12% | -$1.01M |
|
7
Aldeyra Therapeutics
ALDX
$91.7M
| $6.74M | 4.22% |
595,239
+121,793
| +26% | +$1.46M |
|
|
KZR
8
DELISTED
Kezar Life Sciences
KZR
| $5.56M | 3.48% |
102,370
+27,339
| +36% | +$1.55M |
|
|
9
Vertex Pharmaceuticals
VRTX
$121B
| $5.46M | 3.42% |
27,100
-11,250
| -29% | -$2.35M |
|
|
10
Exicure
XCUR
$11.2M
| $5.4M | 3.38% |
24,000
+22,161
| +1,205% | +$5.81M |
|
|
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
| $5.28M | 3.3% |
305,788
+110,788
| +57% | +$2.04M |
|
12
Zimmer Biomet
ZBH
$17.7B
| $5.07M | 3.17% |
32,445
+10,612
| +49% | +$1.72M |
|
|
LKFT
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $4.96M | 3.1% |
72,000
+5,581
| +8% | +$426K |
|
|
CNVY
14
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
| $4.67M | 2.92% |
+410,412
| New | +$4.75M |
|
|
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
| $4.34M | 2.71% |
+181,171
| New | +$4.74M |
|
16
MeiraGTx Holdings
MGTX
$1.09B
| $4.24M | 2.65% |
273,523
-18,421
| -6% | -$263K |
|
|
RCM
17
DELISTED
R1 RCM Inc. Common Stock
RCM
| $3.82M | 2.39% |
+171,817
| New | +$4.15M |
|
|
MORF
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.69M | 2.31% |
64,292
+59,090
| +1,136% | +$3.25M |
|
19
Iovance Biotherapeutics
IOVA
$2.23B
| $3.61M | 2.26% |
+138,886
| New | +$3.61M |
|
|
MTCR
20
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $3.3M | 2.07% |
869,082
+564,597
| +185% | +$2.33M |
|
21
ProQR Therapeutics
PRQR
$243M
| $2.83M | 1.77% |
420,000
-30,165
| -7% | -$195K |
|
22
Quantum-Si Incorporated
QSI
$168M
| $2.79M | 1.74% |
+227,391
| New | +$2.38M |
|
23
UnitedHealth
UNH
$382B
| $2M | 1.25% |
5,000
-1,000
| -17% | -$399K |
|
|
LHCG
24
DELISTED
LHC Group LLC
LHCG
| $1.98M | 1.24% |
9,888
+1,105
| +13% | +$222K |
|
|
25
Aurinia Pharmaceuticals
AUPH
$1.97B
| $1.69M | 1.05% |
130,000
-230,834
| -64% | -$2.94M |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q2 2021 Portfolio in Review
As of Q2 2021, Prosight Management held 54 positions worth $160M, up 31% from $122M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Prosight Management deployed $32.6M of net new capital in Q2 2021, opening 17 new positions and adding to 15 existing holdings. Its largest new stake was Haemonetics: 134,000 shares worth $8.93M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Energy.
On the sell side, the largest reduction was Prothena Corp, an estimated $5.55M trimmed.
- Prosight Management's largest Q2 2021 buy was Haemonetics: 134,000 shares worth $8.93M.
- Prosight Management added most to Exicure in Q2 2021, an estimated $5.81M increase.
- Prosight Management's biggest Q2 2021 reduction was Prothena Corp, cutting an estimated $5.55M.
- Prosight Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $6.04M.
- Prosight Management's ten largest holdings make up 55% of its $160M portfolio in Q2 2021.
- Prosight Management opened 17 new positions and closed 8 in Q2 2021.
- Prosight Management's portfolio value rose 31% quarter-over-quarter to $160M.
Based on Prosight Management's 13F filing for Q2 2021, filed 13 Aug 2021.